Clinical Trials · NCT07307235
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
- Phase
- Phase 4
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Shanghai Zhongshan Hospital
- Enrollment
- 1,316
- Start date
- Dec 2025
- Locations
- See registry
- Primary endpoint
- hemoglobin A1c (HbA1c) change